Evaluating cardioversion outcomes for atrial fibrillation on novel oral anticoagulants versus warfarin: experience at a tertiary referral centre

Evaluating cardioversion outcomes for atrial fibrillation on novel oral anticoagulants versus... Ir J Med Sci (2017) 186:615–620 DOI 10.1007/s11845-017-1582-3 ORIGINAL ARTICLE Evaluating cardioversion outcomes for atrial fibrillation on novel oral anticoagulants versus warfarin: experience at a tertiary referral centre 1 1 1 1 1 1 • • • • • • Z. Sharif B. Srinivas I. Tiedt N. Ryan M. Awadalla V. Sullivan 1 1 1 1,2 • • • D. P. Foley T. Gumbrielle B. McAdam R. G. Sheahan Received: 4 August 2016 / Accepted: 17 February 2017 / Published online: 24 February 2017 Royal Academy of Medicine in Ireland 2017 Abstract elective DCCV and additional anticoagulant monitoring Background Current guidelines recommend anticoagula- was estimated at €1160 per procedure. tion prior to cardioversion in patients with atrial fibrillation Conclusion In elective cardioversions, the group antico- of [48 h or unknown duration to reduce thromboembolic agulated with NOAC was less likely to have subtherapeutic risk. Therapeutic anticoagulation with warfarin, with INR anticoagulation and hence deferred procedures and had between 2 and 3, is consistently achieved in approximately reduced health care consumption when compared to the 60% of patients. group anticoagulated with warfarin. Aims We evaluated outcomes and assessed differences in direct current cardioversion (DCCV) in patients treated Keywords Atrial fibrillation http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Irish Journal of Medical Science (1971 -) Springer Journals

Evaluating cardioversion outcomes for atrial fibrillation on novel oral anticoagulants versus warfarin: experience at a tertiary referral centre

Loading next page...
 
/lp/springer_journal/evaluating-cardioversion-outcomes-for-atrial-fibrillation-on-novel-uDvI0HefCG
Publisher
Springer London
Copyright
Copyright © 2017 by Royal Academy of Medicine in Ireland
Subject
Medicine & Public Health; Internal Medicine; General Practice / Family Medicine
ISSN
0021-1265
eISSN
1863-4362
D.O.I.
10.1007/s11845-017-1582-3
Publisher site
See Article on Publisher Site

Abstract

Ir J Med Sci (2017) 186:615–620 DOI 10.1007/s11845-017-1582-3 ORIGINAL ARTICLE Evaluating cardioversion outcomes for atrial fibrillation on novel oral anticoagulants versus warfarin: experience at a tertiary referral centre 1 1 1 1 1 1 • • • • • • Z. Sharif B. Srinivas I. Tiedt N. Ryan M. Awadalla V. Sullivan 1 1 1 1,2 • • • D. P. Foley T. Gumbrielle B. McAdam R. G. Sheahan Received: 4 August 2016 / Accepted: 17 February 2017 / Published online: 24 February 2017 Royal Academy of Medicine in Ireland 2017 Abstract elective DCCV and additional anticoagulant monitoring Background Current guidelines recommend anticoagula- was estimated at €1160 per procedure. tion prior to cardioversion in patients with atrial fibrillation Conclusion In elective cardioversions, the group antico- of [48 h or unknown duration to reduce thromboembolic agulated with NOAC was less likely to have subtherapeutic risk. Therapeutic anticoagulation with warfarin, with INR anticoagulation and hence deferred procedures and had between 2 and 3, is consistently achieved in approximately reduced health care consumption when compared to the 60% of patients. group anticoagulated with warfarin. Aims We evaluated outcomes and assessed differences in direct current cardioversion (DCCV) in patients treated Keywords Atrial fibrillation

Journal

Irish Journal of Medical Science (1971 -)Springer Journals

Published: Feb 24, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off